• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Mackenzie's Mission HomepageMackenzie's Mission

DONATE Mackenzies Mission Donate
  • Mission
  • About
    • The Story
    • Board
  • Resources
    • Resource List
    • What Is Amyloidosis
  • Speakers Bureau
    • About ASB
    • ASB Operating Committee
  • Fundraisers
  • Blog
  • Contact

amyloidosis

ATTR-CM: Don’t Assume it’s Wild-Type TTR Amyloidosis

May 25, 2023

Historically it has been thought that the majority of elderly cardiomyopathy patients diagnosed with amyloidosis, ATTR-CM, transthyretin amyloid cardiomyopathy, suffered from wild-type, a non-genetic version of the disease that most commonly affects but is not exclusive to men over seventy years of age. A study in the UK conducted from January 2010 through August 2022 was conducted to determine whether this was true. Here we summarize their fascinating findings.

Filed Under: Featured News, Uncategorized, What Is Amyloidosis Tagged With: Amyloid cardiomyopathy, amyloidosis, amyloidosis diagnosis, ATTR amyloidosis, ATTR-CM, ATTRwt, cardiomyopathy, diagnosing amyloidosis, wild-type amyloidosis

Helping Patients Find Their Voice

April 27, 2023

Developing one’s “patient voice” can seem unduly intimidating. Advocating one’s position may come natural to some, but terrifying for others, especially when the physician is viewed as the expert. Additionally, many patients may find it difficult to translate their feelings without having a medical vocabulary. Here are some ideas for healthcare professionals to help their patients find their voice.

Filed Under: Featured News Tagged With: advocacy, amyloidosis, patient advocacy, patient support

Hereditary Amyloidosis: The V122I Variant

March 30, 2023

Despite the evidence that a meaningful 3-4% of the US Black population of West African ancestry likely carries the V122I genetic mutation, hereditary TTR amyloidosis remains significantly underdiagnosed and undertreated in this population. Amyloidosis can be devastating to both patients and their families. Increased awareness of the disease, availability of testing, and FDA-approved therapies are slowly beginning to shift this dynamic. However, there is still much work to be done to close the gap between diagnosed cases and the population estimated to be affected.

Filed Under: Featured News Tagged With: Amyloid cardiomyopathy, amyloidosis, amyloidosis diagnosis, ATTR amyloidosis, attrv, hATTR, hATTR-CM, heart failure, Hereditary Amyloidosis

FACES of Amyloidosis 2023

March 20, 2023

In celebration of Amyloidosis Awareness Month, we are excited to share our FACES of Amyloidosis 2023. Each person in this video is affected by amyloidosis. Wanting to put a face with this disease, they also want you to know they embrace the challenge and fight for living life.

Filed Under: Featured News Tagged With: amyloidosis, FACES 2023, FACES of Amyloidosis, raising awareness

Hereditary Amyloidosis: The T60A Variant

February 23, 2023

Hereditary transthyretin amyloidosis is caused by a genetic mutation which causes misfolding of transthyretin (TTR) proteins (which originate from the liver). There are over 100 genetic variants of hereditary amyloidosis. One such variant, called T60A, is the most common variant in Ireland (and the UK).

Filed Under: Featured News Tagged With: amyloidosis, ATTR amyloidosis, attrv, hATTR, Hereditary Amyloidosis, Irish Variant, T60A

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 19
  • Go to Next Page »

Primary Sidebar

Recent News

  • ATTR-CM: Don’t Assume it’s Wild-Type TTR Amyloidosis
  • Helping Patients Find Their Voice
  • Hereditary Amyloidosis: The V122I Variant
  • FACES of Amyloidosis 2023
  • Hereditary Amyloidosis: The T60A Variant

Be A Part Of Our Mission!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

  • Mission
  • About
  • Resources
  • Speakers Bureau
  • Fundraisers
  • Blog
  • Contact

Registered 501(c)(3) · Contact · Copyright © 2023 · Mackenzies Mission - All Rights Reserved